Business Context and Reporting Period
Kura Oncology, Inc. filed this Form 8-K on January 24, 2018, to report a specific corporate event. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing reports on a capital raise event rather than periodic financial performance. Key metrics include:
- Shares Sold: 3,136,722 shares of common stock.
- Weighted Average Price: $18.85 per share.
- Gross Proceeds: Approximately $59.1 million.
- Remaining Capacity: Up to $40.7 million available for future sales under the existing agreement.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a current report of a single transaction.
Material Changes
The material change reported is the execution of an at-the-market equity offering. The company sold shares pursuant to a sales agreement with Cowen and Company, LLC, originally dated January 27, 2017, and amended on November 9, 2017.
Outlook and Management Commentary
Management indicated that following these sales, the Company may offer and sell additional shares of its common stock having an aggregate offering price of up to $40.7 million from time to time through Cowen pursuant to the sales agreement. No specific risks, contingencies, or unusual items beyond the standard equity offering were detailed in this excerpt.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction to assess dilution impact.
- Confirm the net proceeds after deducting underwriting commissions and offering expenses.
- Review the full sales agreement with Cowen and Company, LLC for specific terms and termination rights.
- Check subsequent filings to determine if the remaining $40.7 million capacity was utilized.